Canada Markets closed

Revive Therapeutics Ltd. (RVV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1800-0.0150 (-7.69%)
At close: 3:59PM EDT

Revive Therapeutics Ltd.

The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Carmelo Marrelli A.C.I.S., B.Com., C.A., C.P.A., CPA, B.Comm., CAChief Financial Officer71.47kN/A1971
Mr. Michael FrankChairman & CEON/AN/A1961
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Revive Therapeutics Ltd., a specialty cannabis company, focuses on the research, development, and commercialization of novel cannabinoid-based products in Canada. Its novel cannabinoid delivery technology is to fill the medical needs for diseases and disorders, such as pain, inflammation, and wound care. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. has strategic partnership with Aximbiotech, Herman Holdings, Sanyal Biotechnology, University of South Carolina, Warf, University of Wisconsin-Madison, and Chemi Pharmaceutical Inc.; and Complete Phytochemical Solutions, LLC to advance research initiatives for psilocybin-based pharmaceutical products. The company was incorporated in 2012 and is based in Toronto, Canada.

Corporate Governance

Revive Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.